Glycoprotein News and Research

RSS

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.

7 Apr 2021

Researchers identify a novel SARS-CoV-2 variant (A.VOI.V2) in southern Africa

Scientists recently explored the transmission dynamics of currently circulating variants of SARS-CoV-2 in a southern African country. By analyzing the genomic sequences of these variants, they have identified a novel SARS-CoV-2 variant with multiple spike mutations. They have temporarily designated the variant A.VOI.V2.

6 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

A research group from the U.S. demonstrated the practicality of a spike display system in order to accelerate vaccine design, but also to swiftly appraise the effects of mutations in emerging strains of the SARS-CoV-2.

5 Apr 2021

Comparative study of SARS, MERS, BAT‐SARS, and SARS-CoV-2

Even though a comparative study on the genomic sequences of SARS-CoV, MERS-CoV, and SARS-CoV-2 is available, there is a gap in the research in regards to the comparison between four types of coronaviruses, namely, SARS-CoV, MERS-CoV, BAT-CoV, and SARS-CoV-2. A new study, which deals with the genomic comparison between the sequence of the above-stated four types of coronaviruses, has been published in the Journal of Medical Virology.

2 Apr 2021

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Researchers at The Scripps Research Institute, USA, have described a potential target for COVID-19 vaccines. Dubbed as CC40.8 bnAb, it exhibited broad reactivity with human beta coronaviruses.

1 Apr 2021

Could a flavonoid found in common fruit and vegetables combat COVID-19?

Researchers in India have gathered and presented a large body of evidence highlight quercetin – a flavonoid molecule found in many common fruits and vegetables – may be developed into drug therapies used to combat COVID-19.

1 Apr 2021

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

New research deals with the development of RBD trimer as a potent target for SARS-CoV-2 subunit vaccines. This study revealed the development of a trimeric RBD subunit vaccine candidate that could induce strong humoral and cellular immune responses in nonhuman primates (NHPs), namely, rhesus macaques.

1 Apr 2021

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

Published in The Lancet, the study explores if the Oxford-AstraZeneca vaccine works well in protecting against the B.1.1.7 variant, otherwise known as the U.K. variant.

31 Mar 2021

Researchers evaluate antibodies that inhibit SARS-CoV-2 RBD variants with a novel assay

A team of researchers recently discussed the potential role of a new assay in bridging a major gap in SARS-CoV-2 research. This assay can throw light on 1) the selection of complementary monoclonal antibody candidates and 2) rapid identification of the immune escape to emerging RBD variants following vaccination or natural infection.

31 Mar 2021

Researchers report on novel SARS-CoV-2 Israeli strain with unique spike glycoprotein

Researchers from Israel describe a novel SARS-CoV-2 strain with a non-synonymous mutation in its spike glycoprotein, designated as P681H; nevertheless, its emergence has not been associated with increased infections rate, facilitated spread or vaccine evasion.

30 Mar 2021

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

In the continued need for next-generation vaccines that confer broad protection against COVID-19, scientists developed an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine.

30 Mar 2021

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Researchers at the Institute of Medical Virology, the University of Zurich in Switzerland, have identified features in the SARS-CoV-2 genome that are important for human respiratory cell growth.

29 Mar 2021

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

In a recent article currently available on the bioRxiv* preprint server, researchers from Belgium and the U.S. demonstrated a robust replication model for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates in primary human epithelial cells at the air-liquid interface and appraised the antiviral effect of selected viral replication inhibitors.

28 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

All viruses mutate as they make copies of themselves to spread and thrive. SARS-CoV-2, the virus the causes COVID-19, is proving to be no different. There are currently more than 4,000 variants of COVID-19, which has already killed more than 2.7 million people worldwide during the pandemic.

23 Mar 2021

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Recently, researchers from the US employed multiple-µs molecular dynamic simulations to compare the relative dynamics, stabilities, and energy differences between the SARS-CoV receptor-binding domain (RBD)-ACE2 and SARS-CoV-2 RBD-ACE2 complexes. The study is published on the preprint server, bioRxiv.

23 Mar 2021

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

To understand the ability of SARS-CoV-2 vaccine-elicited antibodies to neutralize and protect against emerging variants (that are pathogenic) and other sarbecoviruses, a large team of researchers studied immunity by receptor-binding domain nanoparticle vaccines. They showed that a clinical-stage multivalent SARS-CoV-2 receptor-binding domain nanoparticle vaccine (SARS-CoV-2 RBD-NP) protected mice from the SARS-CoV-2-induced disease.

22 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

Glycoprotein News and Research

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers identify a novel SARS-CoV-2 variant (A.VOI.V2) in southern Africa

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

The use of mammalian cell surface display for rapid characterization of SARS-CoV-2 variants

Comparative study of SARS, MERS, BAT‐SARS, and SARS-CoV-2

Study discovers new target on SARS-CoV-2 spike for protective antibodies

Could a flavonoid found in common fruit and vegetables combat COVID-19?

Researchers develop a recombinant SARS-CoV-2 receptor-binding domain trimer vaccine candidate

Oxford-AstraZeneca vaccine effective against B.1.1.7 SARS-CoV-2 variant

Researchers evaluate antibodies that inhibit SARS-CoV-2 RBD variants with a novel assay

Researchers report on novel SARS-CoV-2 Israeli strain with unique spike glycoprotein

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

Study identifies key features in SARS-CoV-2 genome essential for replication in respiratory cells

Selecting SARS-CoV-2 inhibitors in human airway epithelial cells

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

Ai helps identify critical interactions for SARS-CoV-2 spike protein binding to ACE2

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News